NCT05465135View on ClinicalTrials.gov

The Effect of Dihydroartemisinin in PCOS

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

March 23, 2023

Study Completion Date

April 23, 2023

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

Dihydroartemisinin

Dihydroartemisinin 40mg three times a day for 12 consecutive weeks.

Trial Locations (1)

200032

Zhongshan Hospital Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER